[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iib-iii-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iib-iii-nsclc":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100634579","rats-sleeve-lobectomy-after-neo-chemo-io-for-nsclc-100634579",false,"NCT07541521","RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC","Robotic-Assisted Sleeve Lobectomy for Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy","RIDDLE-NSCLC","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status 0-2\n* Histologically confirmed NSCLC\n* AJCC 9th clinical stage IIB-III, M0, deemed resectable or potentially resectable by the multidisciplinary tumour discussion (MDT)\n* Planned neoadjuvant chemo-immunotherapy (PD-1\u002FPD-L1 inhibitor + platinum doublet；additional neoadjuvant thoracic radiotherapy is allowed)\n* Planned curative-intent RATS sleeve lobectomy with systematic nodal dissection\n* Baseline and restaging imaging per protocol (CT ± PET-CT)\n* Complete 30-day postoperative follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Metastatic disease (M1) at baseline or on restaging.\n* No immunotherapy component in neoadjuvant regimen (pure chemotherapy) .\n* Prior systemic therapy or thoracic radiotherapy for the current cancer before starting chemo-IO.\n* Palliative intent or planned non-anatomic resection only (e.g., wedge) when sleeve\u002Flobectomy is indicated oncologically.\n* Clear unresectability at restaging (e.g., multistation bulky N2\u002FN3 not responding; unreconstructable T4 invasion) or MDT consensus against surgery.\n* Contraindication to general anesthesia or prohibitive cardiopulmonary risk precluding sleeve\u002Flobectomy.\n* Active autoimmune disease requiring systemic immunosuppression within 2 years, prior organ transplant, or history of grade ≥2 pneumonitis\u002FILD\n* Uncontrolled infection, pregnancy or breastfeeding, or any intercurrent illness that would compromise participation.","ALL",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are:\n\nWhat is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy?\n\nWhat factors are associated with unsuccessful surgery?\n\nHow do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures?\n\nIn this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.",[24,25,26,27],"Stage IIB-III NSCLC","Sleeve Lobectomy","Robotic Surgery","Neoadjuvant Chemoimmunotherapy",[29,30,31,32,33,34],"stage IIB-III NSCLC","sleeve lobectomy","robotic surgery","neoadjuvant chemoimmunotherapy","perioperative outcomes","difficulty of surgery","RECRUITING","2026-04-16",{"date":38,"type":39},"2026-04-21","ACTUAL",{"date":41,"type":20},"2026-04-13",{"date":43,"type":20},"2027-05-30",{"name":45,"class":46},"Shanghai Chest Hospital","OTHER",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100633544","downstaging-and-rats-after-neo-chemo-io-impact-on-surgical-outcomes-in-nsclc-100633544","NCT07528066","Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC","The Impact of Downstaging on Robotic Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer","DRAGON-NSCLC","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed NSCLC\n* AJCC 9th clinical stage IIB-III, M0, deemed resectable or potentially resectable by the multidisciplinary tumour discussion (MDT)\n* Planned neoadjuvant chemo-immunotherapy (PD-1\u002FPD-L1 inhibitor + platinum doublet; additional neoadjuvant RT is allowed) with curative-intent surgery\n* Received ≥1 cycle of chemo-IO (capture the intended 2-4 cycles)\n* Baseline chest CT±PET-CT within 6 weeks before starting neoadjuvant therapy\n* Restaging 2-6 weeks after last neoadjuvant dose with chest CT±PET-CT\n* Curative-intent resection planned; surgery performed 2-10 weeks after last dose\n* Performing systematic nodal dissection\n* ECOG performance status 0-2.\n* Complete 90-day postoperative follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Metastatic disease (M1) at baseline or on restaging\n* No immunotherapy component in the neoadjuvant regimen (unless enrolled in a prespecified comparator cohort; otherwise exclude from primary analysis)\n* Prior systemic therapy or thoracic radiotherapy for the current lung cancer before starting neoadjuvant chemo-IO\n* Planned neoadjuvant chemoradiation (exclude unless including immunotherapy)\n* Definitive decision against surgery before starting neoadjuvant therapy\n* Active autoimmune disease requiring systemic immunosuppression within 2 years, prior organ transplant, or history of grade ≥2 pneumonitis\u002FILD\n* Uncontrolled infection, pregnancy\u002Flactation, or any condition precluding curative-intent resection per MDT",{"count":57,"type":20},200,"The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung cancer (NSCLC) undergoing robotic-assisted thoracic surgery. The main question it aims to answer is:\n\nIs downstaging after neoadjuvant chemo-immunotherapy associated with better surgical outcomes in patients with stage IIB-III NSCLC undergoing robotic-assisted surgery?\n\nParticipants with resectable or potentially resectable stage IIB-III NSCLC who receive neoadjuvant chemo-immunotherapy as part of their routine clinical care and then undergo curative-intent robotic-assisted surgery will be prospectively enrolled from international centers. Clinical, operative, pathological, and postoperative outcome data will be collected, including R0 resection, the extent of resection, conversion to open surgery, postoperative complications, length of stay, readmission, and mortality.",[27,60,24],"Robotic Pulmonary Resection",[29,62,63,33],"neoadjuvant chemo-immunotherapy","robotic-assisted surgery","2026-04-07",{"date":66,"type":39},"2026-04-14",{"date":68,"type":39},"2026-03-02",{"date":70,"type":20},"2027-03-30",{"name":45,"class":46},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100595992","phase-2-toripalimab-combined-with-chemotherapy-as-adjuvant-therapy-for-non-small-cell-lung-cancer-with-or-without-prior-neoadjuvant-therapy-100595992","NCT07039656","Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy","Toripalimab Combined With Chemotherapy as Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy: A Two-Cohort, Multicenter Phase II Trial","Inclusion Criteria:\n\n1. Signed Informed Consent Form\n2. Patient with age ≥ 18 and ≤75 years old, gender is not limited.\n3. Cohort 1: Histological diagnosis of Stage IB -IIIB NSCLC without anti-cancer treatment; Cohort 2: Histological diagnosis of Stage IIB-III NSCLC with non-MPR or MPR but lymph node positivity after neoadjuvant chemoimmunotherapy; (per American Joint Committee on Cancer staging system (AJCC) staging system, 8th edition)\n4. Participants must have had complete resection of NSCLC 60 days\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n6. Adequate organ function performed within 10 days of treatment initiation\n7. Male or female patients of childbearing potential will voluntarily use an effective method of contraception, e.g., double-barrier contraception, condoms, oral or injectable contraceptives, IUDs, etc., during the study period and for the last 6 months of study drug use. All female patients will be considered of childbearing potential unless the female patient is naturally menopausal, artificially menopausal or sterilised (e.g. hysterectomy, bilateral adnexectomy or radiation ovarian irradiation).\n\nExclusion Criteria:\n\n1. Pathological histology confirmed the diagnosis of small cell lung cancer pathological type;\n2. Treatment with prior systemic chemotherapy at any time\n3. Confirmed EGFR or ALK mutations\n4. Patient has a history of active autoimmune disease or autoimmune disease that may recur\n5. Active hepatitis B and C patients will need to be on relevant antiviral therapy, have HBV-DNA \\\u003C2000 IU\u002Fml (\\\u003C104 copies\u002Fml) and have received anti-HBV therapy for at least 14 days prior to study participation, and continue therapy for the duration of the treatment period; HCV RNA-positive patients must be on antiviral therapy and have a liver function that is within the elevated CTCAE grade 1;\n6. Known allergy to chemotherapy drugs including cisplatin, paclitaxel, albumin-paclitaxel and pemetrexed;\n7. History of allergy to monoclonal antibody drugs\n8. Patients with previous allogeneic stem cell or parenchymal organ transplantation\n9. Having a mental illness or any other condition that renders treatment non-compliant\n10. Patients unable or unwilling to sign the informed consent form\n11. The investigator considered that the patient's condition may affect compliance with the protocol or make participation in this study unsuitable.","18 Years","75 Years",{"count":82,"type":20},211,"INTERVENTIONAL",[85],"PHASE2","This is a two-cohort, multicenter, Phase II study to evaluate the efficacy and safety of 3-4 cycles of toripalimab (JS001) plus chemotherapy followed by toripalimab maintenance treatment up to one year in participants with completely resected non-small cell lung cancer (NSCLC) stratified by prior neoadjuvant treatment status, as measured by disease-free survival (DFS) and overall survival (OS).\n\nResearchers will compare outcomes between two cohorts:\n\n1. Cohort 1: Stage IB-IIIB participants following completely resection without neoadjuvant therapy;\n2. Cohort 2: Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy.",[88,24],"Stage IB-IIIB NSCLC",[90,91,92],"Toripalimab","MRD","Adjuvant therapy","2025-08-03",{"date":95,"type":39},"2025-08-07",{"date":97,"type":39},"2025-01-01",{"date":99,"type":20},"2030-12-31",{"name":101,"class":46},"Wen-zhao ZHONG",1]